1.	Phase I/II Study of UCN-01 and Fludarabine in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-006, NCI-5538, NCT00045513, 5538
2.	Phase II Study of UCN-01 in Patients With Unresectable Advanced or Metastatic Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UCSF-NCI-5522, NCI-5522, NCT00030888, 5522
3.	Phase II Study of UCN-01 and Fluorouracil in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-02049, NCI-5509, 5509, NCT00045747
4.	Phase II Study of UCN-01 and Topotecan in Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-019, NCI-6402, NCT00072267, 6402
5.	UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 7 and over Sponsor: NCI Protocol IDs: 040173, 04-C-0173, NCI-04-C-0173, NCI-6070, 6070, NCT00085319, NCT00082017
6.	UCN-01 and Topotecan in Treating Patients With Small Cell Lung Cancer That Relapsed or Progressed After Previous Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000394175, PMH-PHL-032, NCI-6992, 6992, NCT00098956
7.	UCN-01 in Treating Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000335544, CCC-PHII-33, UCD-200311478-01, CHNMC-PHII-33, NCI-5536, 5536, NCT00072189
8.	Phase I Study of Continuous-Infusion UCN-01 (a Staurosporine Analogue) in Patients With Refractory Solid Tumors or Lymphoma Phase: Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: NCI-95-C-0171N, NCI-T95-0052N, T95-0052
9.	UCN-01 in Treating Patients With Advanced Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: JHOC-J9814, CDR0000066221, U01CA070095, P30CA006973, JHOC-98012305, NCI-T97-0083, NCT00003289
10.	Phase I Study of UCN-01 and Fludarabine in Patients With Recurrent or Refractory Low-Grade or Indolent Lymphoid Malignancies Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-99-C-0127, NCI-T99-0022, T99-0022, NCT00019838
11.	Phase I Study of Fluorouracil With UCN-01 in Patients With Advanced or Refractory Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-9924, NCI-T99-0037, NCT00004059, T99-0037
12.	Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome Phase: Phase I Type: Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: DM99-165, U01CA062461, P30CA016672, MDA-DM-99165, NCI-T99-0100, CDR0000067522, T99-0100, NCT00004263
13.	UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068274, U01CA062505, P30CA033572, CHNMC-PHI-28, NCI-T99-0065, T99-0065, NCT00006464
14.	UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068492, P30CA023108, DMS-9934, NCI-2331, 2331, NCT00012194
15.	Phase I Study of UCN-01 and Irinotecan in Patients With Resistant Solid Tumors or Locally Recurrent or Metastatic Triple-Negative Breast Cancer (Part I Closed to Accrual as of 6/8/2007) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UVACC-SCC-0102, WUSM-SCC-0102, NCI-5582, 5582, NCT00031681
16.	Phase I Study of UCN-01 and Carboplatin in Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSGCC-0143, NCI-5533, NCT00036777, 5533
17.	Phase I Study of UCN-01 and Gemcitabine in Patients With Unresectable or Metastatic Adenocarcinoma of the Pancreas Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MDA-DM-01553, NCI-5510, NCT00039403, 5510
18.	Phase I Study of UCN-01, Fluorouracil, and Leucovorin Calcium in Patients With Metastatic or Unresectable Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-NAVY-01-04, NCI-5535, NCI-02-C-0222, 5535, NCT00042861
19.	Phase I Study of UCN-01 and Prednisone in Patients With Refractory Solid Tumors or Lymphomas Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-02-C-0241, NCI-5694, 5694, NCT00045500
20.	Phase I Study of UCN-01 and Topotecan in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-005, NCI-5518, NCT00045175, 5518
21.	UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: JHOC-J0173, CDR0000257566, U01CA070095, P30CA006973, JHOC-J0173, NCI-5528, 5528, NCT00047242
22.	Phase I Study of UCN-01 in Combination With Perifosine in Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or High Risk Myelodysplastic Syndromes Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSGCC-0507, MSGCC-H-27229-0507, NCI-7311, 7311, NCT00301938